Investors Flerie Invest and Kvika led the $23m round in EpiEndo Pharmaceuticals. New and existing investors that also participated include European Innovation Council and ABC Ventures. “We have followed EpiEndo for some time and have seen impressive progress towards clinical phase of their lead compound EP 395. We are proud to take part in their continuing journey with the aim to deliver substantially improved treatment of COPD,” Carl-Johan Spak, Flerie Invest Senior Advisor.